STAT+: Divergent trial results on cancer vaccines have the field grappling with hard questions

AI Summary

A melanoma vaccine succeeded in a late-stage clinical trial, but the mixed results across cancer-vaccine studies have left researchers weighing how broadly the approach can work. Key questions include whether other vaccines will deliver similar results and whether mRNA technology is suited to the task.

A melanoma vaccine succeeded in a late-stage clinical trial. The question now is whether other cancer vaccines will work — and whether mRNA is up to the task.